Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q3 2025 · $29.9MThe company’s own SEC segment disclosure.
- Product Cell Processing$25.3M85%
- Rental Revenue Evo And Thaw$1.8M6%
- Rental$1.8M6%
- Product Evo And Thaw$968.0K3%
- Service Evo And Thaw$26.0K0%
- Service$26.0K0%
BioLife Solutions, Inc. (BLFS) reported revenue of $28M in Q2 2026 (quarter ended June 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 64% and net income of $45M (158% of revenue). For the full year FY2025, revenue was $96M (+29% year on year) and net income −$4.6M. Its largest product in 2025-Q3 was Product Cell Processing at $25M, 85% of the disclosed total, just ahead of Rental Revenue Evo And Thaw at 6.0%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #2 of 27 by Smart Score